Last reviewed · How we verify

NCT06716190

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

Terminated Phase 1 Last updated 17 March 2026
What this trial tests

Phase 1 trial testing BI 3731579 in Healthy in 30 participants. Terminated before completion.

Timeline
18 December 2024
Primary endpoint
19 May 2025
5 June 2025

Quick facts

Lead sponsorBoehringer Ingelheim
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date18 December 2024
Primary completion19 May 2025
Estimated completion5 June 2025
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of BI 3731579

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Boehringer Ingelheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06716190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing